{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T08:51:29Z","timestamp":1776588689366,"version":"3.51.2"},"reference-count":52,"publisher":"FapUNIFESP (SciELO)","issue":"suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cad. Sa\u00fade P\u00fablica"],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>Ant\u00eddotos e determinados medicamentos s\u00e3o essenciais ao tratamento de algumas intoxica\u00e7\u00f5es e n\u00e3o podem sofrer falhas no abastecimento, sob o risco de prejudicar a sa\u00fade e a seguran\u00e7a da popula\u00e7\u00e3o. O objetivo deste trabalho foi avaliar a disponibilidade de ant\u00eddotos e medicamentos recomendados para o tratamento de intoxica\u00e7\u00f5es no Brasil. A partir de consensos internacionais, foram selecionados 41 ant\u00eddotos para an\u00e1lise, todos sem patente em vig\u00eancia. Desses, 27 s\u00e3o registrados, por\u00e9m 11 est\u00e3o dispon\u00edveis em formas inadequadas ao tratamento de intoxica\u00e7\u00f5es, restando 16 medicamentos comercialmente dispon\u00edveis. Somente um ter\u00e7o dos medicamentos necess\u00e1rios para o tratamento de intoxica\u00e7\u00f5es est\u00e1 inclu\u00eddo na rela\u00e7\u00e3o de medicamentos essenciais do pa\u00eds. Em adi\u00e7\u00e3o, \u00e9 apresentada proposta de suprimento das demandas a um dos ant\u00eddotos, anticorpo antidigoxina, considerando a capacidade de produ\u00e7\u00e3o nacional de imunobiol\u00f3gicos. Os resultados demonstram limita\u00e7\u00e3o da assist\u00eancia adequada aos pacientes intoxicados no pa\u00eds e refor\u00e7am a necessidade urgente de pol\u00edticas p\u00fablicas na \u00e1rea.<\/jats:p>","DOI":"10.1590\/0102-311x00016113","type":"journal-article","created":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T11:58:35Z","timestamp":1384171115000},"page":"s167-s177","source":"Crossref","is-referenced-by-count":7,"title":["Ant\u00eddotos e medicamentos utilizados para tratar intoxica\u00e7\u00f5es no Brasil: necessidades, disponibilidade e oportunidades"],"prefix":"10.1590","volume":"29","author":[{"given":"Tais F.","family":"Galv\u00e3o","sequence":"first","affiliation":[{"name":"Universidade de Bras\u00edlia, Brasil; Universidade Federal do Amazonas, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Bucaretchi","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo M.","family":"De Capitani","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maur\u00edcio G.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Universidade de Bras\u00edlia, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus T.","family":"Silva","sequence":"additional","affiliation":[{"name":"Universidade Federal do Amazonas, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","first-page":"397","article-title":"Drugs and pharmaceuticals: management of intoxication and antidotes","volume":"100","author":"Smith SW","year":"2010","journal-title":"EXS"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.emc.2009.09.009","article-title":"Toxicology: pearls and pitfalls in the use of antidotes","volume":"28","author":"Smollin CG","year":"2010","journal-title":"Emerg Med Clin North Am","ISSN":"https:\/\/id.crossref.org\/issn\/0733-8627","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/clpt.2010.152","article-title":"Antidotes and treatments for chemical warfare\/terrorism agents: an evidence-based review","volume":"88","author":"Rodgers GC","year":"2010","journal-title":"Clin Pharmacol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9236","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1001\/jama.1996.03540180064034","article-title":"Insufficient stocking of poisoning antidotes in hospital pharmacies","volume":"276","author":"Dart RC","year":"1996","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref5","first-page":"198","article-title":"Antidote availability in Quebec hospital pharmacies: impact of N-acetylcysteine and naloxone consumption","volume":"7","author":"Bailey B","year":"2000","journal-title":"Can J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1440-1584.2010.01129.x","article-title":"Availability of antidotes for the treatment of acute poisoning in Queensland public hospitals","volume":"18","author":"Nissen LM","year":"2010","journal-title":"Aust J Rural Health","ISSN":"https:\/\/id.crossref.org\/issn\/1038-5282","issn-type":"print"},{"key":"ref7","first-page":"103","article-title":"Availability of antidotes in hospital pharmacies in Greece","volume":"43","author":"Plataki M","year":"2001","journal-title":"Vet Hum Toxicol","ISSN":"https:\/\/id.crossref.org\/issn\/0145-6296","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2146\/ajhp110014","article-title":"Antidotes for toxicological emergencies: a practical review","volume":"69","author":"Marraffa JM","year":"2012","journal-title":"Am J Health Syst Pharm","ISSN":"https:\/\/id.crossref.org\/issn\/1079-2082","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1017\/S1481803500008058","article-title":"Antidote stocking in British Columbia hospitals","volume":"5","author":"Gorman SK","year":"2003","journal-title":"CJEM"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1067\/mem.2000.108182","article-title":"Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States","volume":"36","author":"Dart RC","year":"2000","journal-title":"Ann Emerg Med","ISSN":"https:\/\/id.crossref.org\/issn\/0196-0644","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2146\/ajhp120129","article-title":"Antidote program in British Columbia","volume":"69","author":"Gair R","year":"2012","journal-title":"Am J Health Syst Pharm","ISSN":"https:\/\/id.crossref.org\/issn\/1079-2082","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1071\/HC12100","article-title":"Access in New Zealand to antidotes for accidental and intentional drug poisonings","volume":"4","author":"Abbott V","year":"2012","journal-title":"J Prim Health Care"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.annemergmed.2011.08.004","article-title":"Using poison center data for national public health surveillance for chemical and poison exposure and associated illness","volume":"59","author":"Wolkin AF","year":"2012","journal-title":"Ann Emerg Med","ISSN":"https:\/\/id.crossref.org\/issn\/0196-0644","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/S1516-31802011000100005","article-title":"Impact of a poison control center on the length of hospital stay of poisoned patients: retrospective cohort","volume":"129","author":"Galv\u00e3o TF","year":"2011","journal-title":"S\u00e3o Paulo Med J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/S0266462312000116","article-title":"Economic evaluation of poison centers: a systematic review","volume":"28","author":"Galv\u00e3o TF","year":"2012","journal-title":"Int J Technol Assess Health Care","ISSN":"https:\/\/id.crossref.org\/issn\/0266-4623","issn-type":"print"},{"key":"ref16","series-title":"Portaria no 298, de 9 de fevereiro de 2010. Institui Grupo de Trabalho para elabora\u00e7\u00e3o de diretrizes para as atividades das \u00e1reas da toxicologia no Sistema \u00danico de Sa\u00fade (SUS)","year":"2010"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1093\/ajhp\/60.22.2345","article-title":"Availability of antidotes in Quebec hospitals before and after dissemination of guidelines","volume":"60","author":"Bailey B","year":"2003","journal-title":"Am J Health Syst Pharm","ISSN":"https:\/\/id.crossref.org\/issn\/1079-2082","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1017\/S1481803500014214","article-title":"Adequacy of antidote stocking in British Columbia hospitals: the 2005 Antidote Stocking Study","volume":"8","author":"Wiens MO","year":"2006","journal-title":"CJEM"},{"key":"ref19","series-title":"Guideline on antidote availability for emergency departments. Appendix 1: stock levels & storage recommendations","year":"2011"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.annemergmed.2009.01.023","article-title":"Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care","volume":"54","author":"Dart RC","year":"2009","journal-title":"Ann Emerg Med","ISSN":"https:\/\/id.crossref.org\/issn\/0196-0644","issn-type":"print"},{"key":"ref21","series-title":"Antidote stocking guidelines for British Columbia Hospitals British Columbia Drug & Poison Information Centre","year":"2013"},{"key":"ref22","series-title":"Manual de diagn\u00f3stico e tratamento de acidentes por animais pe\u00e7onhentos","year":"2001"},{"key":"ref23","series-title":"WHO model list of essential medicines: 17th list","year":"2011"},{"key":"ref24","series-title":"WHO model list of essential medicines for children: 3rd list","year":"2011"},{"key":"ref25","series-title":"Rela\u00e7\u00e3o Nacional de Medicamentos Essenciais: RENAME","year":"2012"},{"issue":"2","key":"ref26","first-page":"CD005085","article-title":"Oximes for acute organophosphate pesticide poisoning","author":"Buckley NA","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref27","series-title":"Resolu\u00e7\u00e3o no 28, de 9 de maio de 2008. Autorizar a importa\u00e7\u00e3o dos medicamentos constantes na lista de medicamentos liberados em car\u00e1ter excepcional destinados unicamente a uso hospitalar ou sob prescri\u00e7\u00e3o m\u00e9dica, cuja importa\u00e7\u00e3o esteja vinculada a uma determinada entidade hospitalar e\/ou entidade civil representativa, para seu uso exclusivo, n\u00e3o se destinando \u00e0 revenda ou ao com\u00e9rcio","year":"2008"},{"key":"ref28","series-title":"Resolu\u00e7\u00e3o da Diretoria Colegiada - RDC no 81, de 5 de novembro de 2008. Disp\u00f5e sobre o regulamento t\u00e9cnico de bens e produtos importados para fins de vigil\u00e2ncia sanit\u00e1ria","year":"2008"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/MAJ.0b013e3181c15442","article-title":"Reassessing the efficacy of digitalis: from routine treatment to evidence-based medicine","volume":"339","author":"Feussner JR","year":"2010","journal-title":"Am J Med Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9629","issn-type":"print"},{"key":"ref30","series-title":"Cardiac glycosides","author":"POISINDEX Managements","year":"2013"},{"key":"ref31","series-title":"UpToDate","first-page":"1","volume-title":"Digitalis (cardiac glycoside) poisoning","author":"Levine M","year":"2012"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3109\/15563650.2011.635149","article-title":"2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report","volume":"49","author":"Bronstein AC","year":"2011","journal-title":"Clin Toxicol (Phila)"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ahj.2003.07.026","article-title":"Congestive heart failure in Latin America: the next epidemic","volume":"147","author":"Cubillos-Garz\u00f3n LA","year":"2004","journal-title":"Am Heart J","ISSN":"https:\/\/id.crossref.org\/issn\/0002-8703","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.recesp.2011.01.022","article-title":"Epidemiolog\u00eda del s\u00edndrome coronario agudo y la insuficiencia cardiaca en Latinoam\u00e9rica","volume":"64","author":"Hern\u00e1ndez-Leiva E","year":"2011","journal-title":"Rev Esp Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0300-8932","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cardfail.2006.02.005","article-title":"Digoxin use and digoxin toxicity in the post-DIG trial era","volume":"12","author":"Hussain Z","year":"2006","journal-title":"J Card Fail","ISSN":"https:\/\/id.crossref.org\/issn\/1071-9164","issn-type":"print"},{"issue":"4","key":"ref36","first-page":"CD005490","article-title":"Antidotes for acute cardenolide (cardiac glycoside) poisoning","author":"Roberts DM","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/0002-9149(91)90334-H","article-title":"Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity","volume":"68","author":"Mauskopf JA","year":"1991","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref38","first-page":"577","article-title":"Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity","author":"Di Domenico RJ","year":"2000","journal-title":"J Cardiovasc Pharmacol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/1074-2484","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1590\/S0104-59701996000100008","article-title":"A produ\u00e7\u00e3o e o desenvolvimento de vacinas no Brasil","volume":"3","author":"Gadelha CAG","year":"1996","journal-title":"Hist Ci\u00eanc Sa\u00fade-Manguinhos"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1590\/S0104-59702003000500012","article-title":"Inova\u00e7\u00e3o em vacinas no Brasil: experi\u00eancia recente e constrangimentos estruturais","volume":"10","author":"Gadelha C","year":"2003","journal-title":"Hist Ci\u00eanc Sa\u00fade-Manguinhos"},{"key":"ref41","series-title":"Produ\u00e7\u00e3o e caracteriza\u00e7\u00e3o da por\u00e7\u00e3o Fab do anticorpo antidigoxina utilizando a tecnologia de phage display","author":"Murata VM","year":"2012"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12033-012-9564-1","article-title":"Anti-digoxin Fab variants generated by phage display","volume":"54","author":"Murata VM","year":"2013","journal-title":"Mol Biotechnol","ISSN":"https:\/\/id.crossref.org\/issn\/1073-6085","issn-type":"print"},{"key":"ref43","series-title":"Discontinuation of digibind"},{"key":"ref44","series-title":"Specialty pharmaceuticals"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1590\/S1413-81232011000900030","article-title":"Padroniza\u00e7\u00e3o das informa\u00e7\u00f5es toxicol\u00f3gicas no Brasil","volume":"16","author":"Galv\u00e3o TF","year":"2011","journal-title":"Ci\u00eanc Sa\u00fade Coletiva"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1590\/S1413-81232012000100009","article-title":"Perfil da mortalidade por intoxica\u00e7\u00e3o com medicamentos no Brasil, 1996-2005: retrato de uma d\u00e9cada","volume":"17","author":"Mota DM","year":"2012","journal-title":"Ci\u00eanc Sa\u00fade Coletiva"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1757-7241-20-49","article-title":"A one-year observational study of all hospitalized acute poisonings in Oslo: complications, treatment and sequelae","volume":"20","author":"Lund C","year":"2012","journal-title":"Scand J Trauma Resusc Emerg Med"},{"key":"ref48","series-title":"UpToDate","first-page":"1","volume-title":"Calcium channel blocker poisoning","author":"Barrueto F","year":"2012"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/toxsci\/kfr113","article-title":"Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference","volume":"122","author":"Adami HO","year":"2011","journal-title":"Toxicol Sci","ISSN":"https:\/\/id.crossref.org\/issn\/1096-6080","issn-type":"print"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.tox.2006.11.065","article-title":"The dilemma of approving antidotes","volume":"233","author":"Steffen C","year":"2007","journal-title":"Toxicology","ISSN":"https:\/\/id.crossref.org\/issn\/0300-483X","issn-type":"print"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tox.2006.07.008","article-title":"Development of antidotes: problems and strategies","volume":"233","author":"Szinicz L","year":"2007","journal-title":"Toxicology","ISSN":"https:\/\/id.crossref.org\/issn\/0300-483X","issn-type":"print"},{"key":"ref52","series-title":"Treating a patient having e.g. acetaminophen overdose, liver failure, cancers, methacrylonitrile poisoning and radio contrast-induced nephropathy, comprises administering a composition comprising acetylcysteine and a pH adjusting agent patent","author":"Pavliv L"}],"container-title":["Cadernos de Sa\u00fade P\u00fablica"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/csp\/v29s1\/a15.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T08:41:39Z","timestamp":1564648899000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0102-311X2013001300015&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":52,"journal-issue":{"issue":"suppl 1","published-print":{"date-parts":[[2013]]}},"alternative-id":["S0102-311X2013001300015"],"URL":"https:\/\/doi.org\/10.1590\/0102-311x00016113","relation":{},"ISSN":["0102-311X"],"issn-type":[{"value":"0102-311X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}